Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Geron Corp
(NQ:
GERN
)
4.540
+0.060 (+1.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Geron Corp
< Previous
1
2
3
4
5
Next >
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 22, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
August 08, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
July 26, 2024
From
Geron
Via
Business Wire
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
July 23, 2024
From
Geron Corporation
Via
Business Wire
Geron Corp. (NASDAQ: GERN) Near Top of Volume Charts in Friday Trading
March 15, 2024
Via
Investor Brand Network
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation: FDA Approval Fuels Stock Price Surge
June 07, 2024
FDA approval paves the way for Geron Corporation's rise as a leader in hematologic malignancy treatments.
Via
MarketBeat
Exposures
Product Safety
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
June 06, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
May 02, 2024
From
Geron Corporation
Via
Business Wire
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
April 25, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2024
From
Geron Corporation
Via
Business Wire
Geron to Participate at Upcoming Investor Conferences in April
April 03, 2024
From
Geron Corporation
Via
Business Wire
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Via
MarketBeat
Exposures
Product Safety
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
March 19, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
March 14, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 22, 2024
From
Geron Corporation
Via
Business Wire
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2024
From
Geron Corporation
Via
Business Wire
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
January 12, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
December 11, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
December 06, 2023
From
Geron Corporation
Via
Business Wire
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
December 04, 2023
From
Geron Corporation
Via
Business Wire
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
November 28, 2023
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2023
From
Geron Corporation
Via
Business Wire
Geron to Participate at Upcoming Investor Conferences in November
November 07, 2023
From
Geron Corporation
Via
Business Wire
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
November 02, 2023
From
Geron Corporation
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.